Giulia Del Duca
Overview
Explore the profile of Giulia Del Duca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazzotta V, Piselli P, Lepri A, Matusali G, Cimini E, Esvan R, et al.
Vaccines (Basel)
. 2025 Jan;
13(1).
PMID: 39852811
Background: The recent resurgence of mpox in central Africa has been declared a new public health emergency of international concern (PHEIC) requiring coordinated international responses. Vaccination is a priority to...
2.
Camici M, Del Duca G, Brita A, Antinori A
Front Cell Infect Microbiol
. 2024 Dec;
14:1501949.
PMID: 39735263
The pathogenesis of long COVID (LC) still presents many areas of uncertainty. This leads to difficulties in finding an effective specific therapy. We hypothesize that the key to LC pathogenesis...
3.
Vergori A, Del Duca G, Borrelli P, Brita A, Pinnetti C, Mastrorosa I, et al.
Heliyon
. 2024 Oct;
10(20):e39431.
PMID: 39469684
Background: We aim to investigate the proportion of patients (pts) with long-term cognitive outcomes (CO) of PACC and identify associated features. Methods: We assessed participants through a neuropsychological assessment. The...
4.
Vergori A, Del Duca G, Lorenzini P, Brita A, Mastrorosa I, Fusto M, et al.
AIDS
. 2024 Oct;
39(3):270-275.
PMID: 39453875
Objectives: The aim was to investigate whether switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/F/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) may improve neuropsychiatric symptoms and neurocognition. Design: Pilot, single-arm, prospective study of persons...
5.
Del Duca G, Parisi E, Artusio F, Cali E, Fraterrigo Garofalo S, Rosso C, et al.
Food Res Int
. 2024 Sep;
194:114871.
PMID: 39232509
Emulsions stabilized via Pickering particles are becoming more and more popular due to their high stability and biocompatibility. Hence, developing new ways to produce effective Pickering particles is essential. In...
6.
Del Duca G, Tavelli A, Mastrorosa I, Aguglia C, Lanini S, Brita A, et al.
Vaccines (Basel)
. 2023 Dec;
11(12).
PMID: 38140166
Background: we aim to investigate attitudes toward vaccination by analyzing empirical factors associated with vaccine acceptance in the Lazio region mpox vaccination (MpoxVax) campaign in Italy. Methods: all subjects who...
7.
Camici M, Gagliardini R, Lanini S, Del Duca G, Mondi A, Ottou S, et al.
Int J Antimicrob Agents
. 2023 Dec;
63(1):107049.
PMID: 38056572
Background: A rapid ART initiation approach can be beneficial in people with advanced HIV disease, in consideration of their high morbidity and mortality. The aim of our study was to...
8.
Mastrorosa I, Del Duca G, Pinnetti C, Lorenzini P, Vergori A, Brita A, et al.
Health Qual Life Outcomes
. 2023 Mar;
21(1):28.
PMID: 36949439
Background: After the acute phase, symptoms or sequelae related to post-COVID-19 syndrome may persist for months. In a population of patients, previously hospitalized and not, followed up to 12 months...
9.
Mastrorosa I, Pinnetti C, Brita A, Mondi A, Lorenzini P, Del Duca G, et al.
Clin Infect Dis
. 2022 Aug;
76(3):e629-e637.
PMID: 35982541
Background: HIV-associated neurocognitive disorders (HAND) have been suggested as persistent even with effective antiretroviral therapy (ART). Aims were to evaluate HAND prevalence and associated factors, in a large cohort of...